Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -13.52% is 28% above its 5-year average of -18.87%, near the high end of its 5-year range (-65.65%–1.58%).
110.78% below its 12-month average of -6.41%.
Reported quarterly EBITDA margin; no daily interpolation. Q2 FY2026 (2026-06-30): 1.58%.
EBITDA MARGIN
-13.52%
EBITDA MARGIN AVG TTM
-6.41%
EBITDA MARGIN AVG 3Y
-23.93%
EBITDA MARGIN AVG 5Y
-18.87%
EBITDA MARGIN AVG 10Y
-26.31%
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-110.78%
CURRENT VS 3Y AVG
+43.51%
CURRENT VS 5Y AVG
+28.36%
CURRENT VS 10Y AVG
+48.62%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Establishment Labs Holdings Inc.
Market Cap
$1.93B
EBITDA Margin
-13.52%
TTM Avg
-6.41%
3Y Avg
-23.93%
5Y Avg
-18.87%
Market Cap
$1.95B
EBITDA Margin
-3042.18%
TTM Avg
-3200.65%
3Y Avg
-2392.49%
5Y Avg
-2392.49%
Market Cap
$1.89B
EBITDA Margin
-864.28%
TTM Avg
-1007.63%
3Y Avg
-1530.50%
5Y Avg
-1530.50%
Market Cap
$1.89B
EBITDA Margin
3.75%
TTM Avg
2.81%
3Y Avg
-0.66%
5Y Avg
-2.07%
Market Cap
$2.01B
EBITDA Margin
7.12%
TTM Avg
6.21%
3Y Avg
-1.19%
5Y Avg
-11.55%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Establishment Labs Holdings Inc. (ESTA) | $1.93B | -13.52% | -6.41% | -23.93% | -18.87% |
| Immunome, Inc. (IMNM)vs › | $1.95B | -3042.18% | -3200.65% | -2392.49% | -2392.49% |
| AxoGen, Inc. (AXGN)vs › | $1.96B | 0.15% | 1.29% | -6.34% | -9.86% |
| Agios Pharmaceuticals, Inc. (AGIO)vs › | $1.89B | -864.28% | -1007.63% | -1530.50% | -1530.50% |
| Azenta, Inc. (AZTA)vs › | $1.89B | 8.41% | 9.50% | 6.21% | 7.73% |
| BioLife Solutions, Inc. (BLFS)vs › | $1.89B | 3.75% | 2.81% | -0.66% | -2.07% |
| Novavax, Inc. (NVAX)vs › | $1.87B | 52.59% | 11.61% | -27.43% | -466.07% |
| Inspire Medical Systems, Inc. (INSP)vs › | $2.01B | 7.12% | 6.21% | -1.19% | -11.55% |
| Mineralys Therapeutics, Inc. (MLYS)vs › | $2.01B | N/A | N/A | N/A | N/A |
| Palvella Therapeutics, Inc. (PVLA)vs › | $1.86B | -157.11% | -157.28% | -157.28% | -157.28% |
Gross Margin
70.5%
EBITDA Margin
-13.5%
Operating Margin
-18.5%
Net Margin
-15.8%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | 1.58% |
| 2026-03-31 | -6.38% |
| 2025-12-31 | -1.80% |
| 2025-09-30 | -3.04% |
| 2025-06-30 | -22.44% |
| 2025-03-31 | -34.75% |
| 2024-12-31 | -36.57% |
| 2024-09-30 | -27.22% |
| 2024-06-30 | -17.59% |
| 2024-03-31 | -19.97% |
| 2023-12-31 | -65.65% |
| 2023-09-30 | -51.40% |
| 2023-06-30 | -25.91% |
| 2023-03-31 | -15.15% |
| 2022-12-31 | -29.86% |
| 2022-09-30 | -22.26% |
| 2022-06-30 | -22.86% |
| 2022-03-31 | -11.91% |
| 2021-12-31 | -23.40% |
| 2021-09-30 | -27.70% |
| 2021-06-30 | -11.35% |
| 2021-03-31 | -3.47% |
| 2020-12-31 | -25.42% |
| 2020-09-30 | -7.87% |
| 2020-06-30 | -84.08% |
| 2020-03-31 | -28.07% |
| 2019-12-31 | -13.72% |
| 2019-09-30 | -34.88% |
| 2019-06-30 | -39.66% |
| 2019-03-31 | -37.32% |
| 2018-12-31 | -47.89% |
| 2018-09-30 | -32.85% |
| 2018-06-30 | -40.91% |
| 2018-03-31 | -15.14% |
| 2017-12-31 | -33.87% |
| 2017-09-30 | -73.96% |
| 2017-06-30 | -57.23% |
| 2017-03-31 | -53.33% |
